The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).
 
Atish Dipankar Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Aptitude Health; Bayer; Journal of Clinical Pathways/Oncology Learning Network; OncLive; Targeted Oncology
Consulting or Advisory Role - Bayer; Clovis Oncology; Dendreon; Lilly; MedaCorp
Research Funding - Bayer; Janssen (Inst)
Travel, Accommodations, Expenses - Genentech
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics
 
Alok Tewari
Stock and Other Ownership Interests - Moderna Therapeutics; Teladoc
Honoraria - UroToday
Consulting or Advisory Role - Best Doctors, Inc
Travel, Accommodations, Expenses - Abbvie
 
David Tomoaki Miyamoto
Research Funding - Cardiff Oncology (Inst)
 
Bose Kochupurakkal
Employment - Amgen (I)
Stock and Other Ownership Interests - Amgen (I)
Research Funding - Lilly (Inst)
 
Leigh Ellis
No Relationships to Disclose
 
Matthew Bandel
No Relationships to Disclose
 
Claire Leisner
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology; Syros Pharmaceuticals; Zentalis
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
 
Alan D. D'Andrea
Stock and Other Ownership Interests - Cedilla Therapeutics; Cyteir; IDEAYA Biosciences
Consulting or Advisory Role - AstraZeneca; Cedilla Therapeutics; Cyteir; IDEAYA Biosciences; Intellia Therapeutics; Lilly; Merck Serono; Sierra Oncology; Third Rock Ventures
Research Funding - Lilly (Inst); Merck Serono (Inst)
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Manifold Bio; Microsoft; Monte Rosa Therapeutics; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Janssen; Manifold Bio; Monte Rosa Therapeutics; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Matthew Freedman
No Relationships to Disclose
 
Mary-Ellen Taplin
Honoraria - Abbvie; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis Oncology; Constellation Pharmaceuticals; GlaxoSmithKline; Guidepoint Global; Incyte; Janssen-Ortho; Merck; Myovant Sciences; Pfizer; Pfizer; Progenics; Research to Practice; Roivant; UpToDate
Consulting or Advisory Role - Arcus Ventures (I); AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals
 
Himisha Beltran
Consulting or Advisory Role - Amgen; AstraZeneca; Blue Earth Diagnostics; Foundation Medicine; Janssen Oncology; Pfizer
Research Funding - Abbvie/Stemcentrx (Inst); Bristol Myers Squibb Foundation (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology